Session » Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II: Models and Mechanisms (1662–1667)
- 1:00PM-1:15PM
-
Abstract Number: 1662
Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial
- 1:15PM-1:30PM
-
Abstract Number: 1663
Tocilizumab for acute exacerbation of rheumatic disease-related interstitial lung disease: A prospective real-world study
- 1:30PM-1:45PM
-
Abstract Number: 1664
Cardiac Sarcoidosis Response to Steroid-Sparing Immunosuppression
- 1:45PM-2:00PM
-
Abstract Number: 1665
Comparative Effectiveness of Biologic Versus Conventional Therapy in Uveitis with Systemic Rheumatic Diseases: Real-World Evidence from a Propensity-Matched Cohort
- 2:00PM-2:15PM
-
Abstract Number: 1666
Treatment with Rilzabrutinib was associated with Rapid and Sustained Reduction in Disease Activity in Patients with IgG4-RD Previously Treated or Naïve to B cell Depletion
- 2:15PM-2:30PM
-
Abstract Number: 1667
Recurrent or Incident Pericarditis With Concurrent Autoimmune Disease: Stable Control With Rilonacept Interleukin-1 Pathway Inhibition